Since the start of 2018, GlaxoSmithKline Trading CJSC, the Russian division of British GSK, has won five competitive bids to supply the drugs against HIV, hepatitis B, C and tuberculosis for the total amount of 1.1 billion rubles.
This follows from the materials posted on the public procurement website. The company filed documents to participate in another competitive bidding (to supply abacavir for more than 40 million rubles), but the contract was awarded to Farmaktivy Capital, a distributor that offered a lower price, reported Kommersant newspaper.
All drugs to be supplied by the division of British company are available in its portfolio. The competitive biddings for two drugs – maraviroc (Celsentri) and dolutegravir (Tivicay) — were for the first time announced by the Russian Ministry of Health under the centralized procurement procedure. Another three drugs (zidovudine, lamivudine and fosamprenavir) were supplied last year by R-Pharm, Irwin 2 and Pharmimex. In GSK, they are represented under such trade names as Retrovir, Epivir and Telzir.
The market participants interviewed by Kommersant said that, earlier, the HIV drugs from GSK participated in public procurement through third-party distributors. But the company found such collaboration disadvantageous. The sources of Kommersant were unable to shed light on who was the partner of GSK. GSK confirmed to Kommersant its decision to participate directly in the supply of HIV drugs to the Ministry of Health.
“This will ensure stability of supplies and contribute to the most optimal planning,” said the company.